Surrozen (NASDAQ:SRZN) Trading Down 12.8% - Should You Sell?

Key Points

• Surrozen, Inc. (NASDAQ:SRZN) experienced a 12.8% drop in stock price, closing at $9.03, with trading volume down by 25% compared to its average.
• Despite the decline, analyst firm HC Wainwright reaffirmed a "buy" rating for Surrozen with a price target of $32.00.
• The company's latest earnings report showed a significant earnings miss, with a reported EPS of -$3.13, compared to an expected -$1.09.

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report)'s stock price fell 12.8% during trading on Thursday . The stock traded as low as $9.03 and last traded at $9.03. 8,460 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 11,261 shares. The stock had previously closed at $10.36.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and set a $32.00 target price on shares of Surrozen in a research note on Monday, May 12th.

Surrozen Stock Performance

The stock has a market capitalization of $85.73 million, a price-to-earnings ratio of -0.69 and a beta of 0.60. The business has a 50-day moving average of $9.07 and a 200-day moving average of $9.84.

Surrozen (NASDAQ:SRZN - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.09. The firm had revenue of $0.98 million during the quarter. Surrozen had a negative return on equity of 842.90% and a negative net margin of 274.42%. On average, research analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Surrozen

A number of large investors have recently bought and sold shares of SRZN. Geode Capital Management LLC grew its holdings in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company's stock worth $277,000 after buying an additional 5,702 shares in the last quarter. 5AM Venture Management LLC acquired a new stake in shares of Surrozen during the first quarter worth $3,615,000. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Surrozen by 37.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 88,653 shares of the company's stock worth $1,034,000 after purchasing an additional 24,000 shares during the last quarter. RA Capital Management L.P. boosted its holdings in shares of Surrozen by 140.3% during the first quarter. RA Capital Management L.P. now owns 679,130 shares of the company's stock worth $7,919,000 after purchasing an additional 396,550 shares during the last quarter. Finally, Nantahala Capital Management LLC raised its position in shares of Surrozen by 17.1% in the 1st quarter. Nantahala Capital Management LLC now owns 229,527 shares of the company's stock worth $2,676,000 after buying an additional 33,504 shares during the period. Institutional investors and hedge funds own 66.57% of the company's stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.